Table 2. Stratified analyses of pooled relative risks (95% CI) of AF for HbA1c levels as continuous variable.
| Stratified analyses | No. of studies | Pooled RR(95% CI) | Heterogeneity test | |
|---|---|---|---|---|
| P value | I2(%) | |||
| style | ||||
| prospective | 3 | 1.11(1.06,1.16) | 0.59 | 0.00% |
| retrospective | 5 | 1.02(0.84,1.24) | <0.01 | 87.50% |
| Country | ||||
| America | 3 | 1.04(0.89,1.21) | <0.01 | 86.60% |
| Not America | 4 | 1.09(0.85,1.41) | <0.01 | 84.10% |
| Publication year | ||||
| before 2011 | 4 | 0.98(0.80,1.20) | <0.01 | 89.80% |
| After 2012 | 4 | 1.20(1.06,1.19) | 0.36 | 5.70% |
| Sample size | ||||
| <3000 | 4 | 1.09(0.82,1.44) | <0.01 | 81.70% |
| ≥3000>ze7H耂 ≥96m>ez7I耂 ≥6>ez71.13(1.09,1.18)J耀 1.13(1.09,1.18)70. |
4 | 1.06(0.96,1.18) | <0.01 | 84.60% |
| Follow-up duration | ||||
| <96m | 2 | 1.16(1.02,1.32) | 0.43 | 0.00% |
| ≥96m>ez7I耂 ≥6>ez71.13(1.09,1.18)J耀 1.13(1.09,1.18)70.83( |
1 | 1.11(1.05,1.16) | . | . |
| age | ||||
| <63y | 2 | 1.12(1.06,1.18) | 0.31 | 4.30% |
| ≥63y | 6 | 1.03(0.88,1.22) | <0.01 | 84.60% |
| prime effect size | ||||
| OR | 5 | 1.02(0.84,1.24) | <0.01 | 87.50% |
| RR | 0 | . | . | . |
| HR | 3 | 1.11(1.06,1.16) | 0.59 | 0.00% |
| CABG | ||||
| Yes | 2 | 0.83(0.70,0.99) | 0.13 | 57.20% |
| No | 6 | 1.13(1.09,1.18) | 0.46 | 0.00% |
| Study quality | ||||
| <6 | 1 | 1.87(0.93,3.76) | . | . |
| ≥6>ez71.13(1.09,1.18)J耀 1.13(1.09,1.18)70.83(0.70,0.99)K耀0.83(0 |
7 | 1.05(0.95,1.16) | <0.01 | 82.20% |
Note: I2 is interpreted as the proportion of total variation across studies that is due to heterogeneity rather than chance; CABG, coronary artery bypass grafting.